新诊断多发性骨髓瘤患者的进展及未来展望

Issam Hamadeh, Shebli Atrash, Ashley Matusz Fisher, Maham A. Khan, Jordan Diana Robinson, Paul Barry, Saad Z. Usmani
{"title":"新诊断多发性骨髓瘤患者的进展及未来展望","authors":"Issam Hamadeh,&nbsp;Shebli Atrash,&nbsp;Ashley Matusz Fisher,&nbsp;Maham A. Khan,&nbsp;Jordan Diana Robinson,&nbsp;Paul Barry,&nbsp;Saad Z. Usmani","doi":"10.1002/acg2.96","DOIUrl":null,"url":null,"abstract":"<p>The overall survival (OS) in multiple myeloma (MM) has almost quadrupled over the past 2 decades. This improvement could be attributed to the introduction of novel agents in the schema of therapy which includes the following phases: induction, high dose melphalan/stem cell transplant, optional posttransplant consolidation and maintenance (Barlogie Total-Therapy schema). Because disease relapse is inevitable, additional treatment is generally needed to achieve remission. Emerging evidence suggests that assessment of minimal residual disease status following induction or autologous stem cell transplant could be predictive of duration of progression-free survival as well as OS. In an effort to prolong duration of first remission, various drug combinations are being evaluated in the front-line setting. The purpose of this paper is to provide a succint review of the current treatment paradigm of newly diagnosed MM and highlight the preliminary findings from some of the ongoing clinical trials which are likely to change current practice.</p>","PeriodicalId":72084,"journal":{"name":"Advances in cell and gene therapy","volume":"4 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-06-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/acg2.96","citationCount":"1","resultStr":"{\"title\":\"Advances & future prospects in newly diagnosed multiple myeloma patients\",\"authors\":\"Issam Hamadeh,&nbsp;Shebli Atrash,&nbsp;Ashley Matusz Fisher,&nbsp;Maham A. Khan,&nbsp;Jordan Diana Robinson,&nbsp;Paul Barry,&nbsp;Saad Z. Usmani\",\"doi\":\"10.1002/acg2.96\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>The overall survival (OS) in multiple myeloma (MM) has almost quadrupled over the past 2 decades. This improvement could be attributed to the introduction of novel agents in the schema of therapy which includes the following phases: induction, high dose melphalan/stem cell transplant, optional posttransplant consolidation and maintenance (Barlogie Total-Therapy schema). Because disease relapse is inevitable, additional treatment is generally needed to achieve remission. Emerging evidence suggests that assessment of minimal residual disease status following induction or autologous stem cell transplant could be predictive of duration of progression-free survival as well as OS. In an effort to prolong duration of first remission, various drug combinations are being evaluated in the front-line setting. The purpose of this paper is to provide a succint review of the current treatment paradigm of newly diagnosed MM and highlight the preliminary findings from some of the ongoing clinical trials which are likely to change current practice.</p>\",\"PeriodicalId\":72084,\"journal\":{\"name\":\"Advances in cell and gene therapy\",\"volume\":\"4 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-06-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1002/acg2.96\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Advances in cell and gene therapy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/acg2.96\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in cell and gene therapy","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/acg2.96","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

摘要

在过去的20年里,多发性骨髓瘤(MM)的总生存期(OS)几乎翻了两番。这种改善可能归因于在治疗方案中引入了新的药物,包括以下阶段:诱导、大剂量美法兰/干细胞移植、可选的移植后巩固和维持(Barlogie总治疗方案)。由于疾病复发是不可避免的,通常需要额外的治疗来达到缓解。新出现的证据表明,诱导或自体干细胞移植后最小残留疾病状态的评估可以预测无进展生存期和OS的持续时间。为了延长首次缓解的持续时间,各种药物组合正在一线进行评估。本文的目的是对目前新诊断的MM的治疗模式进行简要回顾,并强调一些正在进行的临床试验的初步发现,这些试验可能会改变目前的做法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Advances & future prospects in newly diagnosed multiple myeloma patients

The overall survival (OS) in multiple myeloma (MM) has almost quadrupled over the past 2 decades. This improvement could be attributed to the introduction of novel agents in the schema of therapy which includes the following phases: induction, high dose melphalan/stem cell transplant, optional posttransplant consolidation and maintenance (Barlogie Total-Therapy schema). Because disease relapse is inevitable, additional treatment is generally needed to achieve remission. Emerging evidence suggests that assessment of minimal residual disease status following induction or autologous stem cell transplant could be predictive of duration of progression-free survival as well as OS. In an effort to prolong duration of first remission, various drug combinations are being evaluated in the front-line setting. The purpose of this paper is to provide a succint review of the current treatment paradigm of newly diagnosed MM and highlight the preliminary findings from some of the ongoing clinical trials which are likely to change current practice.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信